# DEA Synthetic Opioids Schedule I Placement Updates 2026

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/dea-synthetic-opioids-schedule-i-placement-june-2026/
> **Published:** 2026-06-22T15:09:39-04:00 | **Last Modified / Clinically Audited:** 2026-09-29T00:38:47-04:00
> **Clinical Summary:** Review the latest DEA synthetic opioids schedule I placement updates impacting clinical practice and regulatory compliance in 2026.

---

Policy WatchJune 22, 2026. 20 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score.

Score 70Federal Register

[Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I](https://www.federalregister.gov/documents/2026/04/24/2026-08104/schedules-of-controlled-substances-placement-of-mdmb-4en-pinaca-in-schedule-i)

The DEA placed synthetic cannabinoid MDMB-4en-PINACA into Schedule I, classifying it as having a high potential for abuse and no accepted medical use, impacting clinical practice and legal considerations regarding cannabinoid products.

[Read more →](https://www.federalregister.gov/documents/2026/04/24/2026-08104/schedules-of-controlled-substances-placement-of-mdmb-4en-pinaca-in-schedule-i)

Score 70Federal Register
[Schedules of Controlled Substances: Placement of 3-Methoxyphencyclidine (1-(1-(3-Methoxyphenyl)cyclohexyl)piperidine) in Schedule I](https://www.federalregister.gov/documents/2026/03/23/2026-05618/schedules-of-controlled-substances-placement-of-3-methoxyphencyclidine)

The DEA placed 3-methoxyphencyclidine, a dissociative anesthetic with no accepted medical use, into Schedule I, impacting any potential research involving this substance and clarifying its legal status separate from cannabis.

[Read more →](https://www.federalregister.gov/documents/2026/03/23/2026-05618/schedules-of-controlled-substances-placement-of-3-methoxyphencyclidine)

Score 70Federal Register
[Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I](https://www.federalregister.gov/documents/2026/03/16/2026-05064/schedules-of-controlled-substances-temporary-placement-of-bromazolam-in-schedule-i)

The DEA temporarily placed bromazolam, a benzodiazepine sometimes found as adulterant in illicit cannabis products, into Schedule I, impacting handling and potentially raising concerns for patient safety due to misidentification.

[Read more →](https://www.federalregister.gov/documents/2026/03/16/2026-05064/schedules-of-controlled-substances-temporary-placement-of-bromazolam-in-schedule-i)

Score 70Federal Register
[Schedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I of the Controlled Substances Act](https://www.federalregister.gov/documents/2026/03/02/2026-04112/schedules-of-controlled-substances-placement-of-clonazolam-diclazepam-etizolam-flualprazolam-and)

The DEA placed five benzodiazepine analogs into Schedule I, impacting potential clinical considerations for practitioners evaluating patient-reported use of these substances alongside cannabis.

[Read more →](https://www.federalregister.gov/documents/2026/03/02/2026-04112/schedules-of-controlled-substances-placement-of-clonazolam-diclazepam-etizolam-flualprazolam-and)

Score 70Federal Register
[Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I](https://www.federalregister.gov/documents/2026/01/20/2026-00954/schedules-of-controlled-substances-temporary-placement-of-2-fluorodeschloroketamine-in-schedule-i)

The DEA temporarily placed 2-fluorodeschloroketamine into Schedule I, potentially impacting research and clinical use should this substance be considered as an adjunct therapy alongside cannabis for certain conditions.

[Read more →](https://www.federalregister.gov/documents/2026/01/20/2026-00954/schedules-of-controlled-substances-temporary-placement-of-2-fluorodeschloroketamine-in-schedule-i)

Score 70Federal Register
[Schedules of Controlled Substances: Placement of 4-Fluoroamphetamine in Schedule I](https://www.federalregister.gov/documents/2026/01/15/2026-00633/schedules-of-controlled-substances-placement-of-4-fluoroamphetamine-in-schedule-i)

The DEA placed 4-fluoroamphetamine into Schedule I, potentially impacting research access and clinical use should similar scheduling actions occur with cannabinoids or related compounds.

[Read more →](https://www.federalregister.gov/documents/2026/01/15/2026-00633/schedules-of-controlled-substances-placement-of-4-fluoroamphetamine-in-schedule-i)

Score 70Federal Register
[Schedules of Controlled Substances: Placement of N-Pyrrolidino Metonitazene and N-Pyrrolidino Protonitazene in Schedule I](https://www.federalregister.gov/documents/2026/01/12/2026-00362/schedules-of-controlled-substances-placement-of-n-pyrrolidino-metonitazene-and-n-pyrrolidino)

The DEA placed potent synthetic opioids N-pyrrolidino metonitazene and N-pyrrolidino protonitazene into Schedule I, impacting cannabis clinicians who may encounter patients with co-prescribed medications or polysubstance use disorders.

[Read more →](https://www.federalregister.gov/documents/2026/01/12/2026-00362/schedules-of-controlled-substances-placement-of-n-pyrrolidino-metonitazene-and-n-pyrrolidino)

Score 70Federal Register
[Schedules of Controlled Substances: Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I](https://www.federalregister.gov/documents/2025/12/23/2025-23717/schedules-of-controlled-substances-placement-of-n-desethyl-isotonitazene-and-n-piperidinyl)

The DEA placed two synthetic opioids, N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene, into Schedule I, impacting clinicians needing to differentiate these substances from cannabis when assessing patient substance use or toxicology results.

[Read more →](https://www.federalregister.gov/documents/2025/12/23/2025-23717/schedules-of-controlled-substances-placement-of-n-desethyl-isotonitazene-and-n-piperidinyl)

Score 70Federal Register
[Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I](https://www.federalregister.gov/documents/2025/12/16/2025-22963/schedules-of-controlled-substances-placement-of-4f-mdmb-butica-adb-4en-pinaca-5f-edmb-pica-and)

The DEA placed four synthetic cannabinoids into Schedule I, classifying them as having a high potential for abuse and no accepted medical use, impacting clinical practice and legal considerations regarding cannabinoid products.

[Read more →](https://www.federalregister.gov/documents/2025/12/16/2025-22963/schedules-of-controlled-substances-placement-of-4f-mdmb-butica-adb-4en-pinaca-5f-edmb-pica-and)

Score 70Federal Register
[Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I](https://www.federalregister.gov/documents/2025/12/15/2025-22763/schedules-of-controlled-substances-temporary-placement-of-bromazolam-in-schedule-i)

The DEA temporarily placed bromazolam, a benzodiazepine sometimes found as adulterant in illicit cannabis products, into Schedule I, impacting its legality and clinical use.

[Read more →](https://www.federalregister.gov/documents/2025/12/15/2025-22763/schedules-of-controlled-substances-temporary-placement-of-bromazolam-in-schedule-i)

Score 70Federal Register
[Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I](https://www.federalregister.gov/documents/2025/12/11/2025-22495/schedules-of-controlled-substances-placement-of-cumyl-pegaclone-in-schedule-i)

The DEA placed cumyl-pegaclone, a synthetic cannabinoid, into Schedule I, meaning it has a high potential for abuse and no currently accepted medical use in the United States.

[Read more →](https://www.federalregister.gov/documents/2025/12/11/2025-22495/schedules-of-controlled-substances-placement-of-cumyl-pegaclone-in-schedule-i)

Score 70Federal Register
[Schedules of Controlled Substances: Placement of 4-Chloromethcathinone in Schedule I](https://www.federalregister.gov/documents/2025/11/17/2025-20004/schedules-of-controlled-substances-placement-of-4-chloromethcathinone-in-schedule-i)

The DEA placed 4-chloromethcathinone, a synthetic cathinone unrelated to cannabis, into Schedule I, impacting clinicians by restricting research and patient access should it be encountered in clinical practice.

[Read more →](https://www.federalregister.gov/documents/2025/11/17/2025-20004/schedules-of-controlled-substances-placement-of-4-chloromethcathinone-in-schedule-i)

Score 70Federal Register
[Schedules of Controlled Substances: Temporary Placement of Ethyleneoxynitazene, Methylenedioxynitazene, 5-Methyl Etodesnitazene, N-Desethyl Etonitazene, N-Desethyl Protonitazene, N,N-Dimethylamino Etonitazene, and N-Pyrrolidino Isotonitazene in Schedule I](https://www.federalregister.gov/documents/2025/10/15/2025-19542/schedules-of-controlled-substances-temporary-placement-of-ethyleneoxynitazene-methylenedioxynitazene)

The DEA temporarily placed six synthetic opioids into Schedule I, impacting cannabis clinicians who may encounter these substances during patient assessments for polysubstance use or potential interactions.

[Read more →](https://www.federalregister.gov/documents/2025/10/15/2025-19542/schedules-of-controlled-substances-temporary-placement-of-ethyleneoxynitazene-methylenedioxynitazene)

Score 70Federal Register
[Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I](https://www.federalregister.gov/documents/2025/10/02/2025-19348/schedules-of-controlled-substances-placement-of-mdmb-4en-pinaca-in-schedule-i)

The DEA placed synthetic cannabinoid MDMB-4en-PINACA into Schedule I, classifying it as having a high potential for abuse and no accepted medical use, impacting clinical practice and legal considerations regarding cannabinoid products.

[Read more →](https://www.federalregister.gov/documents/2025/10/02/2025-19348/schedules-of-controlled-substances-placement-of-mdmb-4en-pinaca-in-schedule-i)

Score 70Federal Register
[Schedules of Controlled Substances: Placement of Seven Specific Fentanyl-Related Substances in Schedule I](https://www.federalregister.gov/documents/2025/09/18/2025-18103/schedules-of-controlled-substances-placement-of-seven-specific-fentanyl-related-substances-in)

This temporary scheduling action does not directly impact cannabis but clarifies federal control over fentanyl analogs, potentially affecting [pain management](https://cedclinic.com/cbd-cbg-topicals-for-eczema/) discussions with patients considering alternatives.

[Read more →](https://www.federalregister.gov/documents/2025/09/18/2025-18103/schedules-of-controlled-substances-placement-of-seven-specific-fentanyl-related-substances-in)

Score 70Federal Register
[Schedules of Controlled Substances: Temporary Placement of N-pyrrolidino metonitazene and N-pyrrolidino protonitazene in Schedule I](https://www.federalregister.gov/documents/2025/08/15/2025-15566/schedules-of-controlled-substances-temporary-placement-of-n-pyrrolidino-metonitazene-and)

The DEA temporarily placed potent synthetic opioids N-pyrrolidino metonitazene and N-pyrrolidino protonitazene in Schedule I, impacting clinicians needing to differentiate these substances from cannabis when evaluating patient toxicology reports or altered mental status.

[Read more →](https://www.federalregister.gov/documents/2025/08/15/2025-15566/schedules-of-controlled-substances-temporary-placement-of-n-pyrrolidino-metonitazene-and)

Score 70Federal Register
[Schedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I of the Controlled Substances Act](https://www.federalregister.gov/documents/2025/07/25/2025-14022/schedules-of-controlled-substances-placement-of-clonazolam-diclazepam-etizolam-flualprazolam-and)

The DEA placed five benzodiazepine analogs into Schedule I, impacting potential clinical use and creating legal restrictions for clinicians considering these substances as alternatives or adjuncts to cannabis treatment.

[Read more →](https://www.federalregister.gov/documents/2025/07/25/2025-14022/schedules-of-controlled-substances-placement-of-clonazolam-diclazepam-etizolam-flualprazolam-and)

Score 70Federal Register
[Exempt Chemical Preparations Under the Controlled Substances Act](https://www.federalregister.gov/documents/2025/07/01/2025-12198/exempt-chemical-preparations-under-the-controlled-substances-act)

A 2023 rule clarifies that hemp-derived extracts containing no more than 0.3% delta-9 THC are exempt from Controlled Substances Act regulation, impacting legal access for some patients and clinicians.

[Read more →](https://www.federalregister.gov/documents/2025/07/01/2025-12198/exempt-chemical-preparations-under-the-controlled-substances-act)

Score 70Federal Register
[Schedules of Controlled Substances: Temporary Placement of Seven Benzimidazole-Opioids in Schedule I](https://www.federalregister.gov/documents/2025/06/26/2025-11462/schedules-of-controlled-substances-temporary-placement-of-seven-benzimidazole-opioids-in-schedule-i)

The DEA temporarily placed seven synthetic opioids in Schedule I, impacting research and potentially diverting attention/resources from cannabis studies examining [pain management](https://cedclinic.com/cbd-cbg-topicals-for-eczema/) alternatives.

[Read more →](https://www.federalregister.gov/documents/2025/06/26/2025-11462/schedules-of-controlled-substances-temporary-placement-of-seven-benzimidazole-opioids-in-schedule-i)

Score 70Regulations.gov
[Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene in Schedule I](https://www.regulations.gov/document/DEA-2021-0031-0011)

The DEA placed three synthetic opioids—butonitazene, flunitazene, and metodesnitazene—into Schedule I, meaning they have a high potential for abuse and no currently accepted medical use in the United States.

[Read more →](https://www.regulations.gov/document/DEA-2021-0031-0011)

Digest-Level Clinical Commentary

Dr. Caplan’s Take
This digest reflects the DEA’s sustained enforcement focus on novel synthetic cannabinoids and other designer drugs rather than cannabis itself, which signals that the regulatory landscape for [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) practice remains determined by state-level policy rather than federal scheduling actions. The repeated listings of synthetic cannabinoid analogs like MDMB-4en-PINACA and the emphasis on fentanyl-related substances underscore the [public health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) distinction between regulated cannabis products used in clinical settings and illicit synthetic compounds, a distinction that supports [evidence-based cannabis](https://cedclinic.com/jama-cannabis-review-physician-analysis/) medicine where state law permits. For practitioners in states with legal frameworks, these actions reinforce the importance of patient education regarding unregulated synthetic alternatives while maintaining clinical focus on whole-plant or standardized cannabis preparations with documented cannabinoid profiles.

Clinical Perspective

These regulatory actions reflect the ongoing challenge of synthetic drug proliferation, where clandestine manufacturers continuously modify chemical structures to circumvent existing controlled substance laws. The items listed represent primarily novel synthetic cannabinoids, benzodiazepines, cathinones, and opioid analogs that have emerged in illicit drug markets faster than legislative scheduling can typically address them. From a clinical standpoint, these scheduling actions underscore the importance of maintaining awareness of novel psychoactive substances that may present to emergency departments or [addiction treatment](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) settings with unpredictable potency, toxicity profiles, and clinical effects that often differ substantially from their parent compounds.

Drug EnforcementSynthetic DrugsControlled SubstancesFederal Regulation

💬 Join the Conversation

Have a question about how this applies to your situation?
 [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan)

Want to discuss this topic with other patients and caregivers?
 [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/ask-dr-caplan/)

Have thoughts on this? Share it:

[𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Policy+Watch+%E2%80%94+June+22%2C+2026+%40drcaplan&url=)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Policy+Watch+%E2%80%94+June+22%2C+2026+--+via+%40drcaplan.bsky.social+)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/)

Related Articles

- [Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I](https://cedclinic.com/dea-scheduling-synthetic-cannabinoids-update-2026/)

- [Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I](https://cedclinic.com/cumyl-pegaclone-schedule-i-designation/)

- Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I

[https://cedclinic.com/contact/](https://cedclinic.com/contact/)

Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.

Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance

[Leave a Message](https://cedclinic.com/contact/)
[Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/)
[Medical Consulting](https://cedclinic.com/book/)
[Cannabis Care](https://cedclinic.com/book/)

[https://cedclinic.com/contact/](https://cedclinic.com/contact/)

RELATED READING AT CED CLINIC

Continue exploring the evidence

[Policy Watch: 20 Regulatory Updates — June 21, 2026](https://cedclinic.com/schedules-controlled-substances-placement-june-2026/)

Explore the regulatory changes reported just one day prior, providing context and continuity to the latest controlled substances updates.

[Read June 21 Updates](https://cedclinic.com/schedules-controlled-substances-placement-june-2026/)

[Policy Watch: 20 Regulatory Updates — June 08, 2026](https://cedclinic.com/dea-synthetic-cannabinoids-schedule-i-placement-june-2026/)

Review earlier June regulatory updates to understand evolving trends in synthetic substances and controlled substances scheduling.

[Read June 08 Updates](https://cedclinic.com/dea-synthetic-cannabinoids-schedule-i-placement-june-2026/)

Policy Watch: 19 Regulatory Updates — June 16, 2026

Gain insights from mid-June regulatory developments affecting synthetic cannabinoids and opioids scheduling.

Read June 16 Updates

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).